A European Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Enzalutamide Treatment in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 28 Nov 2017
At a glance
- Drugs Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms PREMISE
- Sponsors Astellas Pharma Europe Ltd
- 10 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 24 Apr 2017 Planned End Date changed from 1 Jul 2018 to 29 Mar 2019.